BOSTON SCIENTIFIC CORP (BSX.DE) Fundamental Analysis & Valuation

FRA:BSX • US1011371077

59.2 EUR
-1.6 (-2.63%)
Last: Mar 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This BSX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

BSX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 65 industry peers in the Health Care Equipment & Supplies industry. BSX has an excellent profitability rating, but there are some minor concerns on its financial health. BSX is not overvalued while it is showing excellent growth. This is an interesting combination. This makes BSX very considerable for growth investing!


Dividend Valuation Growth Profitability Health

8

1. BSX.DE Profitability Analysis

1.1 Basic Checks

  • BSX had positive earnings in the past year.
  • BSX had a positive operating cash flow in the past year.
  • Each year in the past 5 years BSX has been profitable.
  • BSX had a positive operating cash flow in each of the past 5 years.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • With a decent Return On Assets value of 6.64%, BSX is doing good in the industry, outperforming 73.85% of the companies in the same industry.
  • The Return On Equity of BSX (11.96%) is better than 72.31% of its industry peers.
  • BSX has a better Return On Invested Capital (8.70%) than 67.69% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 10.72%.
  • The last Return On Invested Capital (8.70%) for BSX is above the 3 year average (7.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROIC 8.7%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • BSX's Profit Margin of 14.44% is amongst the best of the industry. BSX outperforms 84.62% of its industry peers.
  • BSX's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 19.92%, BSX belongs to the top of the industry, outperforming 81.54% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BSX has grown nicely.
  • BSX has a better Gross Margin (69.01%) than 81.54% of its industry peers.
  • In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
Industry RankSector Rank
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BSX.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
  • BSX has more shares outstanding than it did 1 year ago.
  • BSX has more shares outstanding than it did 5 years ago.
  • BSX has a better debt/assets ratio than last year.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 4.16 indicates that BSX is not in any danger for bankruptcy at the moment.
  • BSX has a Altman-Z score of 4.16. This is in the better half of the industry: BSX outperforms 73.85% of its industry peers.
  • BSX has a debt to FCF ratio of 3.13. This is a good value and a sign of high solvency as BSX would need 3.13 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 3.13, BSX is doing good in the industry, outperforming 72.31% of the companies in the same industry.
  • BSX has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.46, BSX is in line with its industry, outperforming 53.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Altman-Z 4.16
ROIC/WACC0.9
WACC9.7%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 1.62 indicates that BSX should not have too much problems paying its short term obligations.
  • BSX has a Current ratio (1.62) which is in line with its industry peers.
  • BSX has a Quick Ratio of 1.08. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.08, BSX perfoms like the industry average, outperforming 50.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.08
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BSX.DE Growth Analysis

3.1 Past

  • BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.51%, which is quite impressive.
  • BSX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 26.01% yearly.
  • BSX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.88%.
  • BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.16% yearly.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%

3.2 Future

  • Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.13% on average per year.
  • Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 10.46% on average per year.
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue Next Year10.94%
Revenue Next 2Y10.71%
Revenue Next 3Y10.55%
Revenue Next 5Y10.46%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. BSX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 22.42, the valuation of BSX can be described as rather expensive.
  • Based on the Price/Earnings ratio, BSX is valued a bit cheaper than the industry average as 72.31% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 25.71. BSX is around the same levels.
  • The Price/Forward Earnings ratio is 19.55, which indicates a rather expensive current valuation of BSX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
  • BSX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.42
Fwd PE 19.55
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • BSX's Enterprise Value to EBITDA ratio is in line with the industry average.
  • BSX's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 27.73
EV/EBITDA 20.66
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as BSX's earnings are expected to grow with 13.32% in the coming years.
PEG (NY)1.53
PEG (5Y)0.86
EPS Next 2Y13.93%
EPS Next 3Y13.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSX.DE Dividend Analysis

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BSX.DE Fundamentals: All Metrics, Ratios and Statistics

BOSTON SCIENTIFIC CORP

FRA:BSX (3/12/2026, 7:00:00 PM)

59.2

-1.6 (-2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.17%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap87.85B
Revenue(TTM)20.07B
Net Income(TTM)2.90B
Analysts85.5
Price Target91.04 (53.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.84%
Min EPS beat(2)1.62%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)1.62%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)5.56%
EPS beat(12)12
Avg EPS beat(12)5.7%
EPS beat(16)15
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.88%
Max Revenue beat(2)0.96%
Revenue beat(4)3
Avg Revenue beat(4)0.87%
Min Revenue beat(4)-0.88%
Max Revenue beat(4)2.43%
Revenue beat(8)7
Avg Revenue beat(8)1.73%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.59%
PT rev (1m)-15.64%
PT rev (3m)-17.41%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)0.67%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)-0.05%
Revenue NQ rev (1m)-0.32%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)-0.44%
Revenue NY rev (3m)-0.43%
Valuation
Industry RankSector Rank
PE 22.42
Fwd PE 19.55
P/S 5.05
P/FCF 27.73
P/OCF 22.37
P/B 4.19
P/tB N/A
EV/EBITDA 20.66
EPS(TTM)2.64
EY4.46%
EPS(NY)3.03
Fwd EY5.12%
FCF(TTM)2.13
FCFY3.61%
OCF(TTM)2.65
OCFY4.47%
SpS11.72
BVpS14.14
TBVpS-0.62
PEG (NY)1.53
PEG (5Y)0.86
Graham Number28.98
Profitability
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROCE 10.46%
ROIC 8.7%
ROICexc 9.17%
ROICexgc 30.32%
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
FCFM 18.22%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
ROICexc(3y)7.95%
ROICexc(5y)7.36%
ROICexgc(3y)27.25%
ROICexgc(5y)24.65%
ROCE(3y)9.26%
ROCE(5y)8.51%
ROICexgc growth 3Y16.23%
ROICexgc growth 5Y30.87%
ROICexc growth 3Y13.89%
ROICexc growth 5Y25.4%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Debt/EBITDA 2.08
Cap/Depr 64.04%
Cap/Sales 4.36%
Interest Coverage 12.54
Cash Conversion 84.48%
Profit Quality 126.23%
Current Ratio 1.62
Quick Ratio 1.08
Altman-Z 4.16
F-Score7
WACC9.7%
ROIC/WACC0.9
Cap/Depr(3y)61.91%
Cap/Depr(5y)57.64%
Cap/Sales(3y)4.69%
Cap/Sales(5y)4.67%
Profit Quality(3y)127.68%
Profit Quality(5y)132.57%
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.94%
Revenue Next 2Y10.71%
Revenue Next 3Y10.55%
Revenue Next 5Y10.46%
EBIT growth 1Y30.81%
EBIT growth 3Y24.54%
EBIT growth 5Y34.7%
EBIT Next Year24.64%
EBIT Next 3Y16.7%
EBIT Next 5Y14.81%
FCF growth 1Y38.35%
FCF growth 3Y57.4%
FCF growth 5Y29.98%
OCF growth 1Y32.03%
OCF growth 3Y43.76%
OCF growth 5Y24.63%

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 4 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 8 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 22.42 and the Price/Book (PB) ratio is 4.19.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.65% in the next year.